Robotic surgical simulation [0.03%]
机器人手术模拟技术
Michael A Liss,Elspeth M McDougall
Michael A Liss
Robotic surgery has undergone exponential growth and has ever developing utilization. The explosion of new technologies and regulation have led to challenges in training surgeons who desire this skill set. We review the current state of rob...
Robotic surgical training [0.03%]
机器人手术训练
Sharon Ben-Or,L Wiley Nifong,W Randolph Chitwood Jr
Sharon Ben-Or
In July 2000, the da Vinci Surgical System (Intuitive Surgical, Inc) received Food and Drug Administration approval for intracardiac applications, and the first mitral valve repair was done at the East Carolina Heart Institute in May 2000. ...
Future of robotic surgery [0.03%]
机器人手术的未来
Thomas Sean Lendvay,Blake Hannaford,Richard M Satava
Thomas Sean Lendvay
In just over a decade, robotic surgery has penetrated almost every surgical subspecialty and has even replaced some of the most commonly performed open oncologic procedures. The initial reports on patient outcomes yielded mixed results, but...
From the guest editors: robotic-assisted oncologic surgery: present status and future challenges [0.03%]
来自专栏编辑的信函:机器人辅助肿瘤手术:现状与未来挑战
Clarence E Foster rd,Alan T Lefor
Clarence E Foster rd
From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer [0.03%]
从贝伐单抗到塔斯喹莫德:靶向前列腺癌血管生成疗法的发展历程
Michael T Schweizer,Michael A Carducci
Michael T Schweizer
It was first posited in the 1970s that angiogenesis may prove to be a useful target for anticancer therapies. Since then, a number of agents have been developed and tested across a range of tumor types; however, to date, there have unfortun...
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer [0.03%]
靶向MET和血管内皮生长因子受体信号转导治疗去势抵抗性前列腺癌
Richard J Lee,Matthew R Smith
Richard J Lee
Effective management of bone metastases in men with castration-resistant prostate cancer (CRPC) remains an important unmet medical need. MET and vascular endothelial growth factor receptor (VEGFR) are rational targets for intervention in CR...
Robert R Zielinski,Bernhard J Eigl,Kim N Chi
Robert R Zielinski
Important inroads have been made in the understanding and treatment of metastatic prostate cancer in recent years. However, the need for agents targeting novel pathways remains ever present. One such area with promise is through apoptosis o...
Darren Brady,Chris C Parker,Joe M OSullivan
Darren Brady
Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphonate and strontium-89 have been used for decades in the palliation of pain from bone metastases especially from prostate cancer. Emerging evidence of i...
Bone targeted therapies in metastatic castration-resistant prostate cancer [0.03%]
转移性去势抵抗性前列腺癌的骨靶向治疗
Shanna Rajpar,Karim Fizazi
Shanna Rajpar
Prostate cancer is the most common male cancer. About 90% of metastatic patients will develop bone metastases. Bone disease is responsible of pain, deterioration of quality of life and serious bone complications. Proliferation of prostate c...
Philippa Cheetham,Daniel P Petrylak
Philippa Cheetham
Microtubules are dynamic filamentous cytoskeletal proteins that are responsible for cellular integrity and architecture, mitosis, intracellular transport, cell signaling, and gene expression. Tubulin exists in the cell as dimers of α and ...